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ABSTRACT
The abstracts presented at the 2018 International Society for Extracellular Vesicles Annual
Meeting offer unique insight into the newest discoveries related to the biology and applied
use of extracellular vesicles (EVs). As an extension of a recent “Clinical-Wrap Up” discussion at the
International Society for Extracellular Vesicles 2018 Annual Meeting, a systematic review of each
abstract was performed to determine which abstracts could be considered clinical research. Once
the clinical research abstracts were identified, systematic data extraction included: the major
focus of each clinical research abstract; the countries in which the work was done; and the sample
size, if provided in the abstract. Each abstract was reviewed by two independent authors, with a
third author resolving discrepancies in cases of disagreement. 174 out of 656 (27%) unique
abstracts were determined to be clinical research. Oncology was a principal research focus (51
of the 174 clinical research abstracts, 29%). Many other clinical research abstracts presented at
the International Society for Extracellular Vesicles 2018 Annual Meeting focused on the use of
human samples for development of methods for potential application in the clinic. Beyond
oncology and methods development, a wide range of topics was represented, including cardio-
vascular disease, neurodegenerative disease, genetics, and many others. Current research invol-
ving EVs highlights the common, but false dichotomy of science into curiosity-driven basic
science or application-driven clinical research, when in fact both quest for understanding and
intent to apply the findings appeared to drive much of the work at the International Society for
Extracellular Vesicles 2018 Annual Meeting. Using Pasteur’s Quadrant as a framework, we discuss
where the field of EV research is heading and how we may gain insight into the biological
function of EVs in tandem with how they may benefit individual health.
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In his book “Pasteur’s Quadrant,” Donald Stokes wrote
eloquently about the movement of new ideas from the
realm of basic science to large-scale application [1]. He
proposed a model contrasting with what he perceived
to be the dominant understanding: that ideas proceed
from curiosity-driven basic science to applied research
to a development cycle to production and operations.
Rather than dividing research into basic research dri-
ven only by curiosity and applied research concerned
only with effectiveness, he identified a third, hybrid
motivation for some programmes of research. Stokes
described “use-inspired basic science” as a type of
research motivated simultaneously by curiosity and an
intent to apply the results to a real-world problem. He
considered Pasteur an exemplar of this important
approach to research.
The commonly used definitions of clinical research
highlight the false dichotomy of biomedical research
into applied (clinical) research that generates no new
fundamental insights into biology but improves patients’
health and basic science pursued without regard for
application. The commonly used definitions of clinical
research do not require that study participants have a
health problem or that the results of the research will
change the care of patients. Moreover, the common defi-
nitions are broad enough to include research with a
principal motivation to directly improve human health,
to aid in the development of new technologies that might
someday be useful in the clinic, or simply to understand
mechanisms of disease. In this sense, differentiating
between clinical and basic research abstracts is not a
simple matter of distinguishing whether the scientists
involved are concerned or unconcerned with the applica-
tion of their findings. This manuscript arose as an
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extension of one of the authors’ (JBB) comments at the
Clinical Wrap-up of the 2018 International Society for
Extracellular Vesicles Annual Meeting. We recapitulate
the major ideas of that presentation, explaining the types
of clinical research presented at the International Society
for Extracellular Vesicles 2018 Annual Meeting, includ-
ing the major focus of the projects; the country or coun-
tries in which the work was done; and the sample size, if it
was provided. We also propose “Pasteur’s Quadrant” as
an important framework for understanding our emerging
field, beyond the traditional dichotomy of applied versus
basic science.
Methods
The International Society for Extracellular Vesicles 2018
Annual Meeting abstracts book [2] served as the data
source for this project. To ensure robust data extraction
and to evaluate for ambiguity in the classification of
clinical research, two authors (AZ and JBB) created
independent extracts of the data. The analysis workflow
is summarized in Figure 1. First, using a standardized
form (Supplemental Table), both of these authors inde-
pendently examined every abstract in the International
Society for Extracellular Vesicles 2018 Annual Meeting
programme book to identify studies that should be
considered clinical research. For this purpose, the
authors were guided by the concept that clinical research
involves human participants, whether through interven-
tion or materials obtained from interaction with human
participants [3]. To maintain a focus on the new original
science accepted for presentation at the meeting, the
plenary lectures were not included in the analysis. To
measure the agreement between the two authors regard-
ing whether an abstract was clinical research, we calcu-
lated a metric called Cohen’s kappa, which accounts for
chance agreement. After identifying the clinical research
abstracts, the same two authors extracted: 1) the country
or countries in which the work was done; 2) the major
focus of the work; and 3) the sample size, if provided in
the abstract. Abstracts with researchers from more than
one country were tabulated under each country. An
independent third reviewer reconciled any differences.
Analysis was performed using the R statistical software,
version 3.4.3 [4]. To investigate the number of ongoing
or completed clinical trials involving EVs, two searches
of the main United States of American (USA) clinical
trials registration website (clinicaltrials.gov) were con-
ducted. The first search was for the term “exosomes.”
The second search was also for the term “exosomes,” but
results were limited to “interventional” studies that had
results reported in clinicaltrials.gov. Finally, as a means
of highlighting the breadth of topics of abstracts deemed
clinical, five abstracts were selected at random for dis-
cussion from among those abstracts adjudicated as
clinical.
Results
The reviewers informally noted that classifying the
International Society for Extracellular Vesicles 2018
Annual Meeting work as clinical research was ambiguous
in some cases. For example, in some instances, it was
unclear whether the authors obtained clinical samples in
a way that would allow the authors to know the identity of
the study participant, an aspect of the National Institutes
of Health (NIH) definition of clinical research. The
reviewers occasionally came to different conclusions
about whether the work was clinical research
(kappa = 0.85, P < 0.001). After adjudication of these
differences, 174 of 656 (27%) abstracts were determined
to be clinical research. The clinical research abstracts
presented at the International Society for Extracellular
Vesicles 2018 Annual Meeting focused on a wide range
of diseases and applications. These abstracts were placed
in 20 categories of major focus (Figure 2) organized
predominantly around clinical specialties (e.g., cardiovas-
cular medicine), but also including methods develop-
ment. While many categories of clinical research had
fewer than 5 unique abstracts, oncology was a major
focus, comprising 51 of the 174 clinical abstracts (29%).
Of the 174 clinical abstracts, methods development
(22%), cardiovascular medicine (7%), and neurodegen-
erative disorders (7%) were also commonly studied
topics. Many studies investigated the fundamental biolo-
gical effects of vesicles derived from a human biofluid.
Within the major categories (e.g., cardiovascular medi-
cine), specific diseases often constituted the major focus
of clinical research abstracts at the International Society
for Extracellular Vesicles 2018 Annual Meeting. Prostate
cancer was the focus of 10 of the 50 cancer-related clinical
research abstracts, whereas many different cancers were
the topic of a single abstract.
We next extracted features of the clinical research
abstracts. Authors with affiliations in Australia, Europe,
Africa, Asia, South America, and North America
(Figure 3) were represented among the clinical research
abstracts. Researchers in the USA served as authors for
nearly 40 clinical research abstracts presented at the
International Society for Extracellular Vesicles 2018
Annual Meeting. In descending order of author fre-
quency, authors from Spain, Italy, Germany, China,
the Netherlands, Canada, the United Kingdom, and 24
additional countries contributed to abstracts, as well
(Figure 3). Approximately 40% of the clinical abstracts
(70 of 174) included the sample size. For most of the
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International Society for Extracellular Vesicles 2018
Annual Meeting clinical research abstracts for which a
sample size was provided in the abstract, the number of
study participants was fewer than 100 (Figure 4).
To place our findings in a larger context, we
searched clinicaltrials.gov. A search for “exosomes”
yielded 88 search results. However, the same search,
when restricted to interventional studies with results in
clinicaltrials.gov, returned 0 results.
The five randomly selected clinical abstracts reflect
the diversity of the more clinically focused work pre-
sented at this meeting. Abstract PS07.03 focused on
exosomes from both cultured malignant peripheral
nerve sheath tumour cells and the plasma of patients
Extract Data
Remove Plenary Lectures
Classification by Reviewer 1 Classification by Reviewer 2
ISEV 2018 Abstracts
Book
   Standardized 
 Form
  (Supp. Tbl. 1)
    Reviewer 1  
      Clinical     
Abstracts
    Reviewer 2  
      Clinical     
Abstracts
     ISEV 2018 Clinical
Abstracts
Difference Reconciliation by Reviewer 3







Figure 1. Analysis workflow.
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Figure 2. The number of clinical abstracts by category.
Figure 3. The number of clinical abstracts from various countries presented at the 2018 International Society for Extracellular
Vesicles Annual Meeting.
Figure 4. The distribution of sample sizes for clinical abstracts which reported a sample size.
4 M. RAYYAN ET AL.
with neurofibromatosis, highlighting the mix of more
basic and more applied work so common at the
International Society for Extracellular Vesicles 2018
Annual Meeting. PS06.06 described plasma EVs isolated
from study participants during low or high particular
matter days to study the influence of air pollution.
Abstract PF01.14 reports results of an investigation of
extracellular vesicle-associated deoxyribonucleic acid
(DNA) and cell-free DNA in patients with metastatic
melanoma. LBT01.04 reports a method of making good
manufacturing practice-compliant clinical-grade exo-
somes. The final randomly selected clinical abstract
was PF01.18, reporting the use of antibody- and pep-
tide-based enrichment of tumour EVs from the plasma
of patients with prostate cancer, as well as extraction and
analysis of ribonucleic acid (RNA) and DNA.
Discussion
A striking aspect of the clinical research presented at the
International Society for Extracellular Vesicles 2018
Annual Meeting is how many of the abstracts challenge
traditional notions of applied versus basic research. We
found many examples of projects involving the separation
of human EVs to determine their properties when applied
to cells in vitro. Although conducting work of this type
requires an understanding of the regulatory environment
governing human participants’ research, the intent of
many of these studies appeared to be to generate a revised
understanding of biology, rather than to directly improve a
patient-related outcome. This is indeed basic science, even
if it is also clinical research according to the NIH defini-
tion.Why are human samples so often the starting point of
this work? Although the volume of sample available is
greater than from a mouse or rat, we suspect a principal
reason is because studying human biofluids is perceived as
increasing the likelihood that the findings will someday
help patients in the clinic. Many of these studies fall
squarely into Stokes’ third category of research, rather
than pure basic or pure applied research.
Researchers’ country of origin is unimportant in con-
trast to what they contribute to the world. On the other
hand, countries’ funding and regulatory environment
might affect clinical research output. For that reason,
our analysis included mapping of authors’ countries.
The International Society for Extracellular Vesicles 2018
Annual Meeting was truly an international meeting, with
researchers from all continents (except Antarctica) pre-
senting work. The preponderance of abstracts from the
USA is arguably unsurprising in view of its large size
relative to most other countries. It is encouraging to see
that the meeting location remote from the USA did not
prevent US researchers from contributing their work.
Does the lower number of study participants described
in the International Society for Extracellular Vesicles
2018 Annual Meeting clinical research abstracts impugn
the research present at the meeting? By no means. In the
much older and more mature field of cardiovascular
medicine, effective solutions to clinical problems often
exist, requiring sponsors to fund large studies to demon-
strate incremental improvements beyond the current
standard of care. A use-inspired basic research project
intended to determine whether DNA is present in exo-
somes in human plasma, in contrast, does not require
thousands or even hundreds of people. Initial proof of
concept might be provided by a careful n of 1 study with
well-designed controls, in fact. Moreover, a subset of the
clinical studies presented at the International Society for
Extracellular Vesicles 2018 Annual Meeting involved
serial measurement of analytes within individuals, using
samples that were collected with special considerations
for these emerging forms of clinical chemistry. This type
of work involves different challenges compared to studies
with a single point of contact with the patient, and the
resources required for large-scale longitudinal participant
and follow-up in clinical trials might not be available to
investigators doing principally bench-based investigation.
Moreover, within-subjects designs increase the power of
such studies by allowing participants to serve as their own
controls, minimizing noise. Add to these considerations
the greater complexity of bespoke sample collection
methods that facilitate high-quality research on EVs.
Finally, even if a team finds the funds to scale up sample
collection, scaling up vesicle isolation remains a technical
challenge. Thus, the sample sizes in these early clinical
studies are neither surprising, nor disappointing, but a
reflection of the early state of the field. In the final
analysis, the sample sizes reflect restraint on the part of
funding agencies and investigators in pushing forward
into the unknown. How long this degree of restraint will
remain appropriate will be determined by how rapidly
our field develops, which in turn depends upon factors
such as sharing data and protocols.
Most widely read medical journals will not publish
clinical trials that have not been registered, making regis-
tries like clinicaltrials.gov a window on completed and in-
progress clinical trials. Beyond interventional clinical trials,
investigators can register observational clinical studies. The
finding of 0 registered interventional clinical trials with
results in clinicaltrials.gov does not mean that no clinical
trials with an intervention have been done. For example,
once investigators publish their work, they will not neces-
sarily return to clinicaltrials.gov to report results there, as
well. Indeed, an example of a completed clinical trial can
be found in the phase II clinical trial conducted by Besse
et al. [5]. Building on the group’s two prior phase I trials,
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this clinical trial evaluated the efficacy of injected dendritic
cell-derived exosomes in enhancing natural killer cell
immune responses in patients with advanced non-small
cell lung cancer. The primary endpoint of at least 50% of
patients with progression-free survival at 4 months after
cessation of chemotherapy was not met. Nonetheless, this
result does not diminish the importance of these efforts to
improve outcomes in patients with this deadly disease, for
as William Withering recognized in 1785, “. . .the knowl-
edge of what will not do, may sometimes assist us to dis-
cover what will” [6]. While this study was registered with
clinicaltrials.gov, the authors chose publication as the
venue for disseminating the results, rather than posting
them to clinicaltrials.gov. Still, the complete lack of inter-
ventional clinical trials with associated results in clinical-
trials.gov suggests that relatively few such studies have been
completed. Two types of extracellular vesicle-related clin-
ical trials would be of greatest significance to clinical med-
icine: “strategy trials” in which patients are randomized to
extracellular vesicle assay-guided treatment in a rando-
mized trial or the current standard of care, and trials
involving the administration of EVs. Strategy trials have
historically been challenging, in part because of a strong
inclination on the part of participating clinicians to con-
tinue the current standardof care, rather than to randomize
patients. Whether strategy trials involving EVs or trials
involving administration of EVs will become common
remain to be seen.
Some limitations of our analysis bear mention. We
could not be sure in many instances whether the authors
had met the NIH definition of clinical research, which
requires that samples be in some way traceable to the
study participant. Whether or not this aspect of the NIH
definition is met is less relevant to the spirit of this
analysis compared to whether or not clinical samples
were used to push forward the state of the art in extra-
cellular vesicle research. In addition, many abstracts did
not provide the sample size. It is possible that studies of
larger sample size were included in the abstract book but
did not mention the sample size in the abstract. We are
aware of one such instance, the Extracellular RNA
Consortium, which mentioned the number of clinical
samples, but not the number of participants from which
they were obtained. Although the Extracellular RNA
Consortium has a large sample size that we were able
to locate elsewhere, we suspect it is unlikely that most of
the other abstracts with unspecified sample size are
large. Finally, our clinicaltrials.gov search term “exo-
somes” does not necessarily capture all clinical trials
involving EVs, nor do we assume that all studies
returned by that search involve exosomes as the term
is understood in our field. However, the term has the
benefit of being specific, so that it is unlikely to appear
in a study’s entry if the study has no connection to EVs.
For that reason, we consider the term informative for
our survey of clinical research involving EVs.
What’s next for clinical research involving EVs?
Many questions remain to be clarified (Table 1). The
upcoming revision of the Minimal Information
Standards for Extracellular Vesicle Research
(MISEV 2018) should clarify issues relevant to stan-
dardizing extracellular vesicle extraction from
Table 1. Questions to be answered towards the clinical relevance of extracellular vesicle research.







Highly fragmented and incomplete knowledge; unpublished answers
might be known to some groups; answers are likely to be context-
dependent
ISEV Roadmaps for each commonly assayed body fluid
ISO certification At least one ISO-certified method of EV isolation exists More certification of methods
Automatability Few, if any, automated EV isolation methods exist Development of workflows with automated separation
of extracellular vesicles and standardized
interpretation of downstream assay results
Scalability EV isolation is labour-intensive, requiring major investment to scale up
to large numbers of samples
Increased role for robotics in extracellular vesicle
assays
Do assays for clinical use
need to separate pure





Simpler, more easily repeated methods are often more contaminated
with non-extracellular vesicle material
Intensive investigation of the downstream analytical
consequences of pure or less pure separation of
vesicles





Many commercially available methods of isolating extracellular vesicles
do not indicate the exact principle of the assay.
Continued development of open methods concurrent
with commercially destined proprietary processes
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biofluids. A key issue is how to make extracellular
vesicle isolation sufficiently straightforward and
robust for use in a clinical laboratory. One of the
authors (JBB) recently visited his hospital’s clinical
laboratory and became familiar with the methods
used for urinalysis. The process has been made so
simple and automated that it consists of a “dip” of a
stick in a urine sample and the interpretation of a
resulting colour change by a machine. Clinical
laboratories seek methods requiring no more than
trivial sample handling, with a high degree of auto-
mation and with little or no laboratory technician
judgment. How our field can deliver such tests to the
clinical laboratory will be interesting to observe over
time. EVs are poised to aid in our understanding of
pathology and to potentially guide interventions. In
this process, we stand to learn about the biology of
EVs in tandem with their therapeutic potential, ful-
filling the desire of curiosity and applicability, as
Pasteur did generations before.
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